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A generic miltefosine pharmaceutical
product containing no active pharmaceu-
tical ingredient for the treatment of
visceral leishmaniasis emerged in Bangla-
desh for use in the national elimination
programme. Poor-quality drugs for the
treatment of this fatal neglected tropical
disease are life-threatening for the vulner-
able patients using them but also have a
devastating impact on public health and
elimination programmes targeting this
disease. National drug regulators should
take responsibility and ensure without any
concessions that procured drugs for ne-
glected tropical diseases, either innovator
or generic, adhere to international stan-
dards for drug quality and safety.
Introduction
Proper chemotherapy is pivotal in the
management of visceral leishmaniasis (VL,
also known as kala-azar); without an
effective treatment this neglected parasitic
disease is inevitably fatal [1]. Nevertheless,
the few new and safer but more expensive
treatment options that were developed in
the past decade (i.e., liposomal amphoter-
icin B and miltefosine) remain largely out
of reach of the affected rural population
who are most in need, mainly the poorest
of the poor [2–4]. Miltefosine, an alkyl-
phosphocholine drug, is an essential drug
in the management of VL as it is the first
effective oral treatment option with a
reasonable safety profile [5]. Oral miltefo-
sine allows the treatment of VL patients
without an extended period of hospital
admission and thus puts fewer demands on
both patients and health services [6,7].
Miltefosine is currently preferred for
implementation in national VL elimina-
tion programmes [8], although the burden
of high treatment costs incites the explo-
ration of possibilities for a generic milte-
fosine product [9]. Unfortunately, the
precarious position of VL patients was
recently jeopardized as patients in Bangla-
desh were confronted with a new threat:
the emergence of a new miltefosine
product containing no active pharmaceu-
tical ingredient [10,11].
Case Description
Together with Nepal and India, the
government of Bangladesh has committed
to eliminate VL by 2015, supported by the
WorldHealthOrganization (WHO)[8,12].
Interventions in this VL elimination pro-
gramme comprise active case surveillance
and implementation of vector control
management strategies, but also improve-
ment of the availability of appropriate
drugs [13]. Oral miltefosine was recom-
mended for this strategy and was therefore
registered in Bangladesh [14]. Neverthe-
less, problems relating to its procurement
and supply prohibited accessibility of this
treatment and required a less costly alter-
native. Local procurement of miltefosine
was therefore sought and a generic product
supposedly containing miltefosine named
‘‘Miltefos’’ was manufactured by a local
company for use in the Bangladeshi
national elimination programme for VL.
In early 2008, ‘‘Miltefos’’ was implemented
as first-line therapy for VL in Bangladesh
[8]. Although official numbers remain
absent, reports from the field indicated
abnormal ‘‘poor responses in hundreds of
patients’’ after the use of ‘‘Miltefos’’ [8,10],
thereby clearly contradicting high historic
efficacy rates (,95%) of miltefosine in VL
in nearby Indian and Nepalese provinces
[15]. Therefore bioequivalence studies
were planned to compare the local generic
‘‘Miltefos’’ product to the innovator ‘‘Im-
pavido’’ product (Paladin Labs); however,
the validity of the underlying assumption of
pharmaceutical equivalence had to be
established first. For this reason drug
samples were sent from Bangladesh to our
lab to analyze them for their miltefosine
content. To our best knowledge, only two
different ‘‘Miltefos’’ batches were produced
and distributed in Bangladesh and repre-
sentative drug samples from both these
batches of ‘‘Miltefos’’ with respective label
claims of ‘‘10 mg miltefosine’’ and ‘‘50 mg
miltefosine’’ (Figure 1) were analyzed. A
platform of analytical techniques was
developed of which the methodology is
described in more detail elsewhere [11]. A
high-performance liquid chromatography
coupled to tandem mass spectrometry (LC-
MS/MS) method validated for the detec-
tion of miltefosine with a lower limit of
quantitation of 4 ng/ml in human plasma
immediately revealed that no miltefosine
could be identified in methanol extracts of
any of the ‘‘Miltefos’’ capsules, while this
method allowed the irrefutable identifica-
tion and quantification of miltefosine in the
‘‘Impavido’’ capsules [16]. This absence of
miltefosine was confirmed in the crude
‘‘Miltefos’’ capsule contents by Fourier
transform infrared spectroscopy and a
new, simple, and rapid colorimetric test
for miltefosine with a lower limit of
detection of at least 12.5 mg/ml [11].
Near-infrared spectroscopy even allowed
us to confirm this finding without opening
the capsules. Further tests using mass
spectrometry could not identify any other
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dation products of miltefosine, in the
‘‘Miltefos’’ capsule contents besides the
common excipients lactose and microcrys-
talline cellulose [11].
To confirm these findings and to ensure
that the pharmaceutical product under
investigation was the same product that
was being used by Bangladeshi VL
patients, a second representative sample
of ‘‘Miltefos’’ specimens was collected
directly in the field in Bangladesh at a
health centre where VL patients were
under treatment with ‘‘Miltefos’’ at that
time. Furthermore, whole blood samples
from five VL patients who were still under
treatment with ‘‘Miltefos’’ and the exact
blisters that had been used to treat these
patients were collected simultaneously.
Both these blood and drug specimens
were transported to our lab in sealed and
signed envelopes to ensure the integrity of
the parcel in transit. Caserecordforms and
signed statements by the doctors of these
patients indicating the origin and authen-
ticity of the samples were included. The
same analytical techniques as mentioned
above reconfirmed the previous results: no
miltefosine could be identified in these
‘‘Miltefos’’ batches, nor any other active
pharmaceutical ingredient. Storage condi-
tions in Bangladesh or during transport are
not expected to have been of any
influence, given miltefosine’s excellent
stability profile, also in humid and hot
conditions [17]. Moreover, no miltefosine
could be detected in the whole blood
samples of the patients to whom these
‘‘Miltefos’’ capsules were administered.
All these patients were already several
days on ‘‘Miltefos’’ treatment and should
have accumulated substantial miltefosine
blood concentrations because of the
extremely slow elimination of miltefosine
from the body [18]. A real-time reverse-
transcriptase PCR (qRT-PCR) targeting
the Leishmania 18S ribosomal RNA per-
formed on blood of these patients con-
firmed that they were suffering from VL,
indicating the authenticity of the received
samples [19]. Following these findings,
clinical care of the patients was changed
to treatment with intravenous sodium
antimony gluconate. Eventually, ‘‘Milte-
fos’’ was removed from all patient care
regimens throughout Bangladesh and
intravenous sodium antimony gluconate
was re-introduced as first-line therapy for
VL in Bangladesh [8].
Discussion
This case demonstrates that despite
existinginternationalregulations forquality
assurance of medicines, poor-quality drugs
can be distributed through a nationwide
treatment programme in a resource-poor
country and reach patients suffering from a
fatal neglected tropical disease whose
survival depends on good-quality drugs.
The control of anthroponotic VL in South
Asia relies most importantly on early case
detection and effective treatment, thereby
reducing the human reservoir of disease
[20,21]. The use of substandard or coun-
terfeit drugs containing no or a subthera-
peutic amount of active pharmaceutical
ingredient not only severely jeopardizes the
individual health of patients but also these
control efforts for VL. This emphasizes the
need for prioritizing the quality of anti-
infective medicines that are being used in
resource-poor countries to treat neglected
tropical diseases and the development of
simple and rapid methods to assess drug
quality [22–24].
The poor-quality generic miltefosine
product that we investigated can be
considered as a substandard product
according to WHO definitions, since it
never contained any active pharmaceuti-
cal ingredient [25–27]. However, this
product cannot directly be assumed to be
a counterfeit as well, since a fraudulent
motive for the mislabelling of this product
cannot be inferred from our scientific
Figure 1. ‘‘Miltefos’’ blister packs. Backs of blister package ‘‘Miltefos, Miltefosine 50 mg’’ (A) and ‘‘Miltefos, Miltefosine 10 mg’’ (B), respectively.
The name and logo of the manufacturer have been obscured.
doi:10.1371/journal.pntd.0001544.g001
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previous cases of poor-quality drugs have
been described in India, Nepal, and
Sudan, all concerning antimonials and
resulting in unacceptable toxicity and
even death [29–31]. Poor-quality medi-
cines, both substandard and counterfeit,
constitute a major burden on the public
health in resource-poor countries [10,
22,32,33]. Inadequate local drug regula-
tion and law enforcement combined with
poor compliance of local pharmaceutical
industry with good manufacturing prac-
tices (GMP) can lead to high rates of
substandard drug production in resource-
poor countries, but also to a higher degree
of deliberate counterfeiting activities
[22,34]. Antimalarials have most exten-
sively been reported as a victim of
counterfeiting in resource-poor countries,
with a focus on artesunate products
containing no or only a subtherapeutic
amount of active pharmaceutical ingredi-
ent [35–37]. Provision of free or inexpen-
sive antimalarials has been mentioned as
one of the possible solutions to this
widespread problem, removing the finan-
cial incentive for counterfeiters [32]. It
has also been suggested that the quality of
drugs would be warranted if distributed
‘‘through official institutions’’ [4]. How-
ever, this case clearly underlines that
provision of free anti-infectives—even
through official institutions—does not
necessarily imply that the problem of
poor-quality anti-infectives in resource-
poor countries is resolved and strict
monitoring of drug quality by the funding
organizations or responsible government
bodies is therefore key in any drug
provision programme.
Without ignoring the ongoing debate on
the various definitions of ‘‘substandard’’
and ‘‘counterfeit’’ [22–24,27,34,38], the
emphasis in tackling poor-quality drugs
should be on the safety of patients and
public health, especially in resource-poor
countries and certainly concerning the
treatment of life-threatening diseases.
Shifting the focus from intellectual prop-
erty or trade issues towards public health
and patients to define and combat poor-
quality drugs is therefore urgently needed
[38]. Quality assurance of pharmaceutical
products should be guaranteed by appro-
priate (government) bodies that have the
specific mandate to protect individuals and
public health, and should not be the
responsibility of vulnerable individual
patients themselves [34,39]. In resource-
poor countries it remains cumbersome to
provide this protection, partly due to an
urgent lack of both drug regulatory
capacity and regional analysis laboratories
for quality control of medicines. Previous-
ly, it has been shown that GMP compliant
facilities can have parallel productions
with lower standards for poorly regulated
countries [34]. Quality assurance should
therefore specifically extend to assessment
of each manufacturing site and each
product dossier according to the rigorous
criteria set by the WHO for each individ-
ual drug that is being procured [40].
Several programmes have been initiated
by the WHO (most notably the WHO
Prequalification Programme) but separate-
ly also by other organizations (e.g.,
Me ´decins Sans Frontie `res) to facilitate
qualification of drugs and access to
technical expertise on this topic [34,41].
Unfortunately, the WHO Prequalification
Programme selectively focuses on good-
quality medicinal products relating to
HIV/AIDS, tuberculosis, malaria, influ-
enza, and reproductive health and has
thus far ignored medicines against neglect-
ed diseases, although the availability of
general technical expertise could help
support regulatory authorities with limited
capacities. This case indicates that it may
be needed to extend the WHO Prequal-
ification Programme to drugs for VL and
other neglected diseases.
Availability and accessibility of regula-
tory information and technical expertise
such as methods of analysis and identifi-
cation for drugs for neglected diseases
need to be prioritized. Currently, no
monograph on miltefosine has been in-
cluded in any of the major international
pharmacopoeias, although the drug has
been added to the WHO Model List of
Essential Medicines and has received
approval in Germany, which has a
stringent regulatory authority [42,43].
International pharmacopoeias should
cease to neglect drugs for neglected
diseases to facilitate the quality control of
these medicines and the production of
generic pharmaceutical products. Further-
more, no formal approval of miltefosine or
‘‘Miltefos’’ could be traced in the publicly
available information of the Bangladeshi
drug regulatory authorities [44], despite
WHO documents mentioning the regis-
tration of miltefosine in Bangladesh [14].
Full transparency of the current regulatory
status of medicinal products is simply a
prerequisite for the safe and effective use
of drugs for neglected diseases, certainly in
the resource-poor countries that are most
affected.
Nevertheless, all these outstanding ef-
forts can only be effective when national
or regional drug regulators and procure-
ment programmes in resource-poor coun-
tries are aware of the devastating impact
of poor-quality drugs and decide to make
use of all the (technical) resources that
could be provided to them by interna-
tional agencies. It must be emphasized
that these recommendations certainly do
not reject a priori the production or
procurement of generic pharmaceutical
products as a cheaper alternative for the
treatment of neglected tropical diseases;
however, no concessions should be toler-
ated in terms of assurance of quality and
safety of these medicines, either innovator
or generic.
Conclusion
VL patients belong to the poorest
quintile of the population of resource-poor
countries [3], which make them highly
dependent on drug donations or drug
provision by national elimination pro-
grammes for the treatment of their fatal
disease. These extremely vulnerable pa-
tients deserve to be protected by national
or regional drug regulators who should
take responsibility by implementing the
necessary precautions to prevent repetition
of this poor-quality drug case. All pro-
cured VL drugs either used in the
respective national VL elimination pro-
grammes, available over the counter, or
used in clinical trials need to adhere to the
WHO standards for quality and safety,
irrespective of the country of origin of
these drugs, whether they are innovator or
generic medicines and whether they are
intended to be used in resource-rich or
resource–poor countries. Only under this
condition can VL patients trust in a safe
treatment, and national elimination pro-
grammes might have an impact on this
typically neglected disease.
Ethics Statement
Written informed patient consent was
obtained for the blood samples. Institu-
tional review board approval was not
required, since patients were not treated
in the context of a study and the described
procedures on the blood samples were
performed to ensure that these patients
received adequate treatment.
www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1544References
1. Sengupta PC (1947) History of kala-azar in India.
Indian Med Gaz 82: 281–286.
2. Sundar S, Murray HW (2005) Availability of
miltefosine for the treatment of kala-azar in India.
Bull World Health Organ 83: 394–395.
3. Boelaert M, Meheus F, Sanchez A, Singh SP,
Vanlerberghe V, et al. (2009) The poorest of the
poor: a poverty appraisal of households affected
by visceral leishmaniasis in Bihar, India. Trop
Med Int Health 14: 639–644.
4. den Boer M, Argaw D, Jannin J, Alvar J (2011)
Leishmaniasis impact and treatment access. Clin
Microbiol Infect 17: 1471–1477.
5. Sindermann H, Engel J (2006) Development of
miltefosine as an oral treatment for leishmaniasis.
Trans R Soc Trop Med Hyg 100 Suppl 1:
S17–S20.
6. Meheus F, Balasegaram M, Olliaro P, Sundar S,
Rijal S, et al. (2010) Cost-effectiveness analysis of
combination therapies for visceral leishmaniasis
in the Indian subcontinent. PLoS Negl Trop Dis
4: e818. doi:10.1371/journal.pntd.0000818.
7. Vanlerberghe V, Diap G, Guerin PJ, Meheus F,
Gerstl S, et al. (2007) Drug policy for visceral
leishmaniasis: a cost-effectiveness analysis. Trop
Med Int Health 12: 274–283.
8. World Health Organization - Regional Office for
South-East Asia (2010) Programme manager’s
meeting on elimination of Kala-azar in the South-
East Asia Region, Faridabad, Haryana, India,
17–19 February 2009. Available: http://www.
searo.who.int/LinkFiles/Kala_azar_Rec-09.pdf.
Accessed 7 May 2012.
9. World Health Organization (WHO) (2010)
WHO Technical Report Series 949: Annex 6 -
Costs of medicines in current use for the
treatment of leishmaniasis. Available: http://
www.who.int/leishmaniasis/research/978_92_4_
12_949_6_Annex6.pdf. Accessed 7 May 2012.
10. Senior K (2008) Global health-care implications
of substandard medicines. Lancet Infect Dis 8:
666.
11. Dorlo TPC, Eggelte TA, de Vries PJ, Beijnen JH
(2012) Characterization and identification of
suspected counterfeit miltefosine capsules. Analyst
137: 1265–1274.
12. Bhattacharya SK, Sur D, Sinha PK, Karbwang J
(2006) Elimination of leishmaniasis (kala-azar)
from the Indian subcontinent is technically
feasible & operationally achievable. Indian J Med
Res 123: 195–196.
13. Sundar S, Mondal D, Rijal S, Bhattacharya S,
Ghalib H, et al. (2008) Implementation research
to support the initiative on the elimination of kala
azar from Bangladesh, India and Nepal–the
challenges for diagnosis and treatment. Trop
Med Int Health 13: 2–5.
14. World Health Organization - Regional Office for
South-East Asia (2007) Regional Technical Ad-
visory Group on Kala-azar Elimination - Report
of the Second Meeting, Kathmandu, Nepal, 30
October–2 November 2006. Available: http://
searo.who.int/LinkFiles/Kala_azar_VBC-93.pdf.
Accessed 7 May 2012.
1 5 .B h a t t a c h a r y aS K ,S i n h aP K ,S u n d a rS ,
Thakur CP, Jha TK, et al. (2007) Phase 4 trial
of miltefosine for the treatment of Indian visceral
leishmaniasis. J Infect Dis 196: 591–598.
16. Dorlo TPC, Hillebrand MJX, Rosing H,
Eggelte TA, de Vries PJ, et al. (2008) Develop-
ment and validation of a quantitative assay for the
measurement of miltefosine in human plasma by
liquid chromatography-tandem mass spectrome-
try. J Chromatogr B Analyt Technol Biomed Life
Sci 865: 55–62.
17. German Drug Registration Authorities (2008)
Impavido 10/50 mg Kapseln- Fachinformation.
Available: http://www.pharmnet-bund.de/
dynamic/de/index.html. Accessed 15 February
2010.
18. Dorlo TPC, van Thiel PPAM, Huitema ADR,
Keizer RJ, de Vries HJC, et al. (2008) Pharma-
cokinetics of miltefosine in Old World cutaneous
leishmaniasis patients. Antimicrob Agents Che-
mother 52: 2855–2860.
1 9 .v a nd e rM e i d eW ,G u e r r aJ ,S c h o o n eG ,
Farenhorst M, Coelho L, et al. (2008) Compar-
ison between quantitative nucleic acid sequence-
based amplification, real-time reverse transcrip-
tase PCR, and real-time PCR for quantification
of Leishmania parasites. J Clin Microbiol 46:
73–78.
20. Boelaert M, Criel B, Leeuwenburg J, Van
Damme W, Le Ray D, et al. (2000) Visceral
leishmaniasis control: a public health perspective.
Trans R Soc Trop Med Hyg 94: 465–471.
21. Desjeux P (2004) Leishmaniasis: current situation
and new perspectives. Comp Immunol Microbiol
Infect Dis 27: 305–318.
22. Newton PN, Green MD, Ferna ´ndez FM (2010)
Impact of poor-quality medicines in the ‘‘devel-
oping’’ world. Trends Pharmacol Sci 31: 99–101.
23. Newton PN, Lee SJ, Goodman C, Ferna ´ndez FM,
Yeung S, et al. (2009) Guidelines for field surveys
of the quality of medicines: a proposal. PLoS Med
6: e1000052. doi:10.1371/journal.pmed.1000
052.
24. Fernandez FM, Hostetler D, Powell K, Kaur H,
Green MD, et al. (2011) Poor quality drugs:
grand challenges in high throughput detection,
countrywide sampling, and forensics in develop-
ing countries. Analyst 136: 3073–3082.
25. World Health Organization (WHO) (2005)
Counterfeit & substandard drugs - Frequently
asked questions. Available: http://www.who.int/
medicines/services/counterfeit/faqs/en/. Ac-
cessed 11 March 2011.
26. World Health Organization (WHO) (2009) What
are substandard medicines? Available: http://
www.who.int/medicines/services/counterfeit/
faqs/06/en/index.html. Accessed 6 January
2012.
27. World Health Organization (WHO) (2010) New





cessed 6 January 2012.
28. World Health Organization (WHO) (2008)
Counterfeit medical products. Executive Board
124th session provisional agenda item 4.11
(EB124/14). Available: http://apps.who.int/gb/
ebwha/pdf_files/EB124/B124_14-en.pdf. Ac-
cessed 6 January 2012.
29. Sundar S, Sinha PR, Agrawal NK, Srivastava R,
Rainey PM, et al. (1998) A cluster of cases of
severe cardiotoxicity among kala-azar patients
treated with a high-osmolarity lot of sodium
antimony gluconate. Am J Trop Med Hyg 59:
139–143.
30. Rijal S, Chappuis F, Singh R, Boelaert M,
Loutan L, et al. (2003) Sodium stibogluconate
cardiotoxicity and safety of generics. Trans R Soc
Trop Med Hyg 97: 597–598.
31. Boelaert M, Le Ray D, Van Der Stuyft P (2002)
How better drugs could change kala-azar control.
Lessons from a cost-effectiveness analysis. Trop
Med Int Health 7: 955–959.
32. Newton PN, Green MD, Ferna ´ndez FM,
Day NPJ, White NJ (2006) Counterfeit anti-
infective drugs. Lancet Infect Dis 6: 602–613.
33. Leslie T, Kaur H, Mohammed N, Kolaczinski K,
Ord RL, et al. (2009) Epidemic of Plasmodium
falciparum Malaria Involving Substandard Anti-
malarial Drugs, Pakistan, 2003. Emerg Infect Dis
15: 1753–1759.
34. Caudron J-M, Ford N, Henkens M, Mace ´C ,
Kiddle-Monroe R, et al. (2008) Substandard
medicines in resource-poor settings: a problem
that can no longer be ignored. Trop Med Int
Health 13: 1062–1072.
35. Newton PN, Ferna ´ndez FM, Planc ¸on A,
Mildenhall DC, Green MD, et al. (2008) A
collaborative epidemiological investigation into
the criminal fake artesunate trade in South East
Asia. PLoS Med 5: e32. doi:10.1371/jour-
nal.pmed.0050032.
36. Newton PN, Dondorp A, Green M, Mayxay M,
White NJ (2003) Counterfeit artesunate antima-
larials in southeast Asia. Lancet 362: 169.
37. Dondorp AM, Newton PN, Mayxay M, Van
Damme W, Smithuis FM, et al. (2004) Fake
antimalarials in Southeast Asia are a major
impediment to malaria control: multinational
cross-sectional survey on the prevalence of fake
antimalarials. Trop Med Int Health 9:
1241–1246.
38. Newton PN, Amin AA, Bird C, Passmore P,
Dukes G, et al. (2011) The primacy of public
health considerations in defining poor quality
medicines. PLoS Med 8: e1001139. doi:10.1371/
journal.pmed.1001139.
39. Ravinetto RM, Cloe ¨z S, Scouflaire-Mallet S-M,
Vandenbergh D (2009) Poor-quality medicines in
developing countries. Lancet Infect Dis 9:
267–268.
40. World Health Organization (WHO) (2011)
WHO Technical Report Series 961: WHO
Expert Committee on Specifications for Pharma-
ceutical Preparations, Forty-fifth Report. Avail-
able: http://whqlibdoc.who.int/trs/WHO_
TRS_961_eng.pdf. Accessed 18 October 2011.
41. World Health Organization (WHO) (2010) Pre-
qualification of Medicines Programme - a United
Nations programme managed by the WHO.
Available: http://apps.who.int/prequal/. Ac-
cessed 25 July 2011.
42. World Health Organization (WHO) (2011) 17th
WHO Model List of Essential Medicines. Avail-
able: http://whqlibdoc.who.int/hq/2011/
a95053_eng.pdf. Accessed 24 January 2012.
43. Paladin Labs Inc (2010) Application for inclusion




cessed 13 December 2011.
44. Directorate General of Drug Registration, Gov-
ernment of the People’s Republic of Bangladesh
(2011) Directorate General of Drug Administra-
tion website. Available: http://www.dgda.gov.
bd/. Accessed 18 October 2011.
www.plosntds.org 4 May 2012 | Volume 6 | Issue 5 | e1544